biostudies-literatureUnknown29(3)Hur MHKorean Liver FoundationKorea Radioembolization AssociationKorean Association for Study of the LiverSirtex Technology PTY LTD<h4>Background/aims</h4>Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT.<h4>Methods</h4>This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS).Clinical and molecular hepatology763-778https://www.ebi.ac.uk/biostudies/studies/S-EPMC10366806biostudies-literatureTransarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.PMC10366806Lee HACho YKim GMLee JSHyun DKim DYPark JWHur MHKim YJLee IJKim HCSeo YSSinn DHfalseTransarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.<h4>Background/aims</h4>Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT.<h4>Methods</h4>This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS).2023-01-01T00:00:00Z2023 Jul2025-04-05T14:52:10.714Z2025-02-19T00:26:29.768ZS-EPMC103668063725448810.3350/cmh.2023.0076